Patient’s own immune cells effective as living medicine for melanoma

Cloud computing banner background for smart city

A patient’s own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The TIL trial is the world’s first comparative phase 3 trial looking into the effect of T cell therapy in melanoma, and solid tumors in general.

‘Mad God’ was a 30-year religious experience for Phil Tippett

Previous article

AI can reveal hidden bias in news media

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations